MannKind Corporation reported second quarter 2026 total revenues of $109.4 million, a 43% increase from the prior year period. The company achieved three major growth catalysts: FDA approval for Afrezza in pediatric patients, FDA approval for the Furoscix ReadyFlow autoinjector for heart failure and chronic kidney disease edema, and positive Phase 1b data for nintedanib DPI in idiopathic pulmonary fibrosis. Furoscix generated $22.2 million in net sales during the quarter. MannKind closed a $50 million private placement on July 24, 2026, to fund a $45 million Contingent Value Right payment triggered by the Furoscix ReadyFlow approval. The company reported a net loss of $19.0 million for the quarter and holds $111 million in cash and investments as of June 30, 2026. MannKind Corporation is a biopharmaceutical company developing and commercializing treatments for cardiometabolic and orphan lung diseases.

MannKind Corporation entered into a Securities Purchase Agreement for a $50 million private placement of common stock and pre-funded warrants. The company will use the proceeds to fund a $45 million contingent value rights payment obligation triggered by the FDA approval of Furoscix ReadyFlow. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases.